FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014386844> ?p ?o ?g. }

• W3014386844 endingPage "75" @default.
• W3014386844 startingPage "73" @default.
• W3014386844 abstract "What effects do pharmacological treatments for delirium have on the duration of delirium in critically ill adults?Delirium is one of the most common behavioral manifestations of acute brain dysfunction in patients in intensive care units (ICUs), affecting up to 80% of those who are critically ill.1 Delirium is characterized by inattention, altered consciousness, and disorganized thinking, and it is associated with various serious adverse outcomes including hospital and ICU mortality, longer duration of mechanical ventilator support, prolonged ICU and hospital stays, and long-term cognitive impairment.2 For this reason, nurses must appropriately manage delirium to minimize adverse outcomes.Treatment options include both pharmacological and nonpharmacological interventions, although serious illness often requires a pharmacological treatment. The effectiveness of such regimens vary and are not standardized internationally.2 The most common pharmacological interventions are antipsychotic medications, yet published evidence provides mixed support for their use. A Cochrane systematic review by Burry et al3 compared the 6 main types of medications and assessed their impact on delirium in critically ill patients.This summary describes the review by Burry et al,3 which included data from 14 randomized controlled trials with a combined total of 1844 participants. The review explored 1 primary outcome: Duration of delirium (ie, the time from when delirium was identified until it resolved) measured in days.The randomized controlled trials evaluated by Burry et al3 compared various medications with placebo:The review also evaluated various secondary outcomes:Burry et al3 independently assessed the risk of bias in each study, including selection, performance, detection, attrition, reporting, and publication biases. They resolved any disagreements by reviewing and discussing the data together.The authors used medians and means with 95% CIs as measures of treatment effects among various comparisons and outcomes. They used the internationally approved Grades of Recommendation, Assessment, Development and Evaluation approach to determine the quality of evidence for each outcome. This approach assigns a level of high, moderate, low, or very low regarding the confidence of an outcome or conclusion: (1) high, which indicates that further research is very unlikely to change the confidence in the conclusion; (2) moderate, which means that further research is likely to have an important impact on the confidence in the conclusion and may change it; (3) low, which indicates that further research is very likely to have an important impact on the confidence in the conclusion and is likely to change it; and (4) very low, which means the conclusion is uncertain.4When each drug class was directly compared with a placebo, only the α2-adrenergic agonist dexmedetomidine reduced the duration of delirium; the cholinesterase inhibitor rivastigmine prolonged the duration. Both of these results are based on findings from a single small study. The other drugs, when compared with placebo, did not change delirium duration. In addition, the results did not indicate that any drug reduced the duration of coma, the length of stay, or mortality, nor did the drugs improve long-term cognitive outcomes. Some results did show that dexmedetomidine shortened the duration of mechanical ventilation.The following points provide additional detail about the main results of this systematic review.Delirium continues to be a challenge in the critical care setting, and health care teams continue to use pharmacological interventions to treat it. The main outcomes explored in the systematic review by Burry et al3 suggest that the α2-adrenergic agonist dexmedetomidine may help shorten the duration of both delirium and mechanical ventilation, but those results are based on the findings of only a single small study. No other pharmacological intervention—including antipsychotics, the medication most commonly prescribed for treating delirium—had any effect on delirium duration or on any of the secondary outcomes.One key result was that the cholinesterase inhibitor rivastigmine was associated with harm and a longer stay in the ICU; as such, clinicians should advocate against and carefully consider its use for treating delirium in patients in the ICU. One study showed advantages to using dexmedetomidine to treat delirium in such patients, but additional evidence is needed to fully support this. Health care teams should evaluate the options and make the most appropriate clinical decision on the basis of the best available evidence. The results of ongoing studies such as the international work from the group Del-COrS (Development of core outcome sets for effectiveness trials of interventions to prevent and/or treat delirium) may provide further insight into and guidance regarding delirium management.5Advocating for the best evidence-based treatment is an important part of our role as nurses caring for critically ill patients. We must always consider the best available evidence and understand the feasibility, appropriateness, meaningfulness, and effectiveness of any intervention to determine whether it is appropriate for our particular patient." @default.
• W3014386844 created "2020-04-10" @default.
• W3014386844 creator A5073911558 @default.
• W3014386844 date "2020-04-01" @default.
• W3014386844 modified "2023-09-27" @default.
• W3014386844 title "Pharmacological Treatments for Delirium in Critically Ill Adults" @default.
• W3014386844 cites W2756148215 @default.
• W3014386844 cites W2761211786 @default.
• W3014386844 cites W2950056007 @default.
• W3014386844 cites W2972175093 @default.
• W3014386844 doi "https://doi.org/10.4037/ccn2020430" @default.
• W3014386844 hasPublicationYear "2020" @default.
• W3014386844 type Work @default.
• W3014386844 sameAs 3014386844 @default.
• W3014386844 citedByCount "0" @default.
• W3014386844 crossrefType "journal-article" @default.
• W3014386844 hasAuthorship W3014386844A5073911558 @default.
• W3014386844 hasConcept C118552586 @default.
• W3014386844 hasConcept C126322002 @default.
• W3014386844 hasConcept C142724271 @default.
• W3014386844 hasConcept C168563851 @default.
• W3014386844 hasConcept C17744445 @default.
• W3014386844 hasConcept C177713679 @default.
• W3014386844 hasConcept C197934379 @default.
• W3014386844 hasConcept C199539241 @default.
• W3014386844 hasConcept C204787440 @default.
• W3014386844 hasConcept C27081682 @default.
• W3014386844 hasConcept C27415008 @default.
• W3014386844 hasConcept C2776376669 @default.
• W3014386844 hasConcept C2776412080 @default.
• W3014386844 hasConcept C2779473830 @default.
• W3014386844 hasConcept C2779753318 @default.
• W3014386844 hasConcept C2780494398 @default.
• W3014386844 hasConcept C2987404301 @default.
• W3014386844 hasConcept C2991859549 @default.
• W3014386844 hasConcept C71924100 @default.
• W3014386844 hasConceptScore W3014386844C118552586 @default.
• W3014386844 hasConceptScore W3014386844C126322002 @default.
• W3014386844 hasConceptScore W3014386844C142724271 @default.
• W3014386844 hasConceptScore W3014386844C168563851 @default.
• W3014386844 hasConceptScore W3014386844C17744445 @default.
• W3014386844 hasConceptScore W3014386844C177713679 @default.
• W3014386844 hasConceptScore W3014386844C197934379 @default.
• W3014386844 hasConceptScore W3014386844C199539241 @default.
• W3014386844 hasConceptScore W3014386844C204787440 @default.
• W3014386844 hasConceptScore W3014386844C27081682 @default.
• W3014386844 hasConceptScore W3014386844C27415008 @default.
• W3014386844 hasConceptScore W3014386844C2776376669 @default.
• W3014386844 hasConceptScore W3014386844C2776412080 @default.
• W3014386844 hasConceptScore W3014386844C2779473830 @default.
• W3014386844 hasConceptScore W3014386844C2779753318 @default.
• W3014386844 hasConceptScore W3014386844C2780494398 @default.
• W3014386844 hasConceptScore W3014386844C2987404301 @default.
• W3014386844 hasConceptScore W3014386844C2991859549 @default.
• W3014386844 hasConceptScore W3014386844C71924100 @default.
• W3014386844 hasIssue "2" @default.
• W3014386844 hasLocation W30143868441 @default.
• W3014386844 hasOpenAccess W3014386844 @default.
• W3014386844 hasPrimaryLocation W30143868441 @default.
• W3014386844 hasRelatedWork W1549849946 @default.
• W3014386844 hasRelatedWork W1965599346 @default.
• W3014386844 hasRelatedWork W2161071282 @default.
• W3014386844 hasRelatedWork W2312614777 @default.
• W3014386844 hasRelatedWork W2405796024 @default.
• W3014386844 hasRelatedWork W2728088686 @default.
• W3014386844 hasRelatedWork W2764234746 @default.
• W3014386844 hasRelatedWork W2990448780 @default.
• W3014386844 hasRelatedWork W3031229399 @default.
• W3014386844 hasRelatedWork W2185321621 @default.
• W3014386844 hasVolume "40" @default.
• W3014386844 isParatext "false" @default.
• W3014386844 isRetracted "false" @default.
• W3014386844 magId "3014386844" @default.
• W3014386844 workType "article" @default.